**Synaptogenix, Inc. Announces New Collaboration Agreement with LSU Health New Orleans for Pre-Clinical Testing of PUFA Analogs in Spinal Cord Injury Treatment**
Synaptogenix, Inc. (SNPX), a biopharmaceutical company, has entered into a new collaboration agreement with LSU Health New Orleans' Neuroscience Center of Excellence. This partnership aims to conduct pre-clinical testing on the company’s polyunsaturated fatty acid (PUFA) analogs as a potential treatment for spinal cord injury (SCI).
Furthermore, Synaptogenix has announced that the U.S. Patent and Trademark Office (USPTO) has recently issued US Patent No. 12,016,837. This patent, titled "Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Neurodegenerative Diseases," covers the company’s family of analogs. The forthcoming studies will compare these analogs with Bryostatin in SCI research.
Synaptogenix holds exclusive rights to its PUFA analogs through a licensing agreement with Cognitive Research Enterprises, Inc. (CRE), formerly known as the Blanchette Rockefeller Neurosciences Institute.
